Protein expression in salivary glands of rats with streptozotocin diabetes.
Diabetes mellitus (DM) is a widespread disease with high morbidity and health care costs. An experimental animal model was employed, using morphological and biochemical methods, to investigate the effects of DM on the expression and compartmentation of salivary gland proteins. The distribution of proline-rich proteins (PRP), submandibular mucin (Muc10) and the regulatory (RI and RII) subunits of cyclic AMP-dependent protein kinase type I and type II was determined in the parotid and submandibular (SMG) glands of rats treated with streptozotocin. Quantitative immunocytochemistry of secretory granules in diabetic glands revealed decreases of 30% for PRP in both the parotid and SMG, and a 40% decrease in Muc10 in the SMG. Immunogold labelling showed that RII decreased in nuclei and the cytoplasm in diabetic acinar cells while labelling of secretory granules was similar in control and diabetic parotid. Electrophoresis and Western blotting of tissue extracts of two secretory proteins showed that the response to DM and insulin treatment was gland specific: PRP showed little change in the SMG, but decreased in the parotid in DM and was partially restored after insulin treatment. Photoaffinity labelling showed only RI present in the SMG and mainly RII in the parotid. The results of this and previous studies demonstrating highly specific changes in salivary protein expression indicate that the oral environment is significantly altered by DM, and that oral tissues and their function can be compromised. These findings may provide a basis for future studies to develop tests using saliva for diabetic status or progression in humans.
Mednieks
Maija I
MI
Department of Oral Health, School of Dental Medicine, University of Connecticut, Farmington, CT 06030, USA. mednieks@nso1.uchc.edu
Szczepanski
Andrew
A
Clark
Brett
B
Hand
Arthur R
AR
D000818:Animals; D015153:Blotting, Western / Q000379:methods; D054743:Cyclic AMP-Dependent Protein Kinase Type I / Q000032:analysis / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000378:metabolism*; D004591:Electrophoresis, Polyacrylamide Gel; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007150:Immunohistochemistry; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D046529:Microscopy, Electron, Transmission; D009077:Mucins / Q000032:analysis / Q000378:metabolism; D010306:Parotid Gland / Q000737:chemistry / Q000378:metabolism; D019920:Photoaffinity Labels; D011897:Random Allocation; D051381:Rats; D011916:Rats, Inbred F344; D012469:Salivary Glands / Q000737:chemistry* / Q000378:metabolism; D055273:Salivary Proline-Rich Proteins / Q000032:analysis / Q000378:metabolism; D012471:Salivary Proteins and Peptides / Q000032:analysis* / Q000378:metabolism; D013363:Submandibular Gland / Q000737:chemistry / Q000378:metabolism
D007004:Hypoglycemic Agents; D007328:Insulin; D009077:Mucins; C543540:Oprpn protein, rat; D019920:Photoaffinity Labels; D055273:Salivary Proline-Rich Proteins; D012471:Salivary Proteins and Peptides; D054743:Cyclic AMP-Dependent Protein Kinase Type I